ANXA1 and diabetes mellitus: Inhibition of inflammation has recently been noted as an effective strategy to delay the progression of aging.[27] ANXA1 has been investigated in several age‐associated diseases, such as atherosclerosis, diabetes, and neurodegenerative diseases, in which it exerts its anti‐inflammatory effects by inhibiting platelet‐leukocyte aggregation,[28] promoting neutrophil clearance,[29] and regulating macrophage differentiation.[30] However, the role of ANXA1 in aging remains unclear.